公开(公告)号：US11884647B2

公开(公告)日：2024-01-30

申请号：US17072844

申请日：2020-10-16

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  ATENGEN, INC.

发明人： Hui Sun ,  Pu Sun ,  Guo Cheng ,  Adrian Chichuen Au ,  Ming Zhong

IPC分类号： C07D401/14 ,  A61P35/00 ,  C07D215/42 ,  C07D215/44 ,  C07D215/46 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D417/12 ,  C07D487/08 ,  C07D491/113 ,  C07D498/04 ,  C07H15/26

CPC分类号： C07D401/14 ,  A61P35/00 ,  C07D215/42 ,  C07D215/44 ,  C07D215/46 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D417/12 ,  C07D487/08 ,  C07D491/113 ,  C07D498/04 ,  C07H15/26

摘要： The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.

公开(公告)号：US20210147525A1

公开(公告)日：2021-05-20

申请号：US17072952

申请日：2020-10-16

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  ATENGEN, INC.

发明人： HUI SUN ,  Adrian Chichuen Au ,  Guo Cheng ,  Pu Sun

IPC分类号： C07K16/18

摘要： Pathogenic blood vessels are blood vessels that are not involved in the vascularization of normal organs but are in the pathogenic tissues such as the new blood vessels that drive vision diseases or the blood vessels in tumors that tumors depend on to survive. The current disclosure provides an advancement over typical anti-angiogenic strategies that target the generation of new blood vessels by providing compositions and methods that can selectively target and kill existing pathogenic blood vessels. The conventional antiangiogenic drugs or factors inhibit angiogenesis (the growth of new blood vessels), but cannot effectively kill existing pathogenic blood vessels. Agents, including small molecule compounds and antibodies, have been identified that bind to and activate PLXDC1 and PLXDC2 proteins, leading to effective killing of the endothelial cells in pathogenic blood vessels in vision diseases and in tumors that express these proteins. The disclosure thereby provides a novel modality for eliminating or reducing existing pathogenic blood vessels, thereby treating diseases such as diabetic retinopathy, age-related macular degeneration (AMD), retinopathy of prematurity, and cancer.

公开(公告)号：US20210147385A1

公开(公告)日：2021-05-20

申请号：US17072844

申请日：2020-10-16

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  ATENGEN, INC.

发明人： HUI SUN ,  Pu Sun ,  Guo Cheng ,  Adrian Chichuen Au ,  Ming Zhong

IPC分类号： C07D401/14 ,  A61P35/00 ,  C07D215/46 ,  C07D215/42 ,  C07D401/04 ,  C07D215/44 ,  C07D491/113 ,  C07D401/12 ,  C07H15/26 ,  C07D487/08 ,  C07D405/14 ,  C07D498/04 ,  C07D405/12 ,  C07D417/12 ,  C07D409/12

摘要： The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.